Shanghai Pharmaceutical announced that the self-developed “I031 tablets” received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”).
上海医药：上I031获得临床试验批准通知书
Shanghai Pharmaceutical: Clinical trial approval notice obtained on I031
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.